FDA Warning Letters
This article was originally published in The Silver Sheet
Two additional Siemens Healthcare Diagnostics facilities issued letters due to QS problems and other violations; Covidien cited for QS and MDR troubles in relation to its DUET device.
You may also be interested in...
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.